Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology | GenomeWeb

Traversa Therapeutics this month closed a Series B round worth $5 million, RNAi News has learned.

The cash infusion, combined with an expected revenue stream related to the sale of research products incorporating the company's RNAi-delivery technology, is expected to give the firm enough cash to fund its planned operations through 2010, Traversa President and CEO Hans Petersen told RNAi News yesterday.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.